tradingkey.logo
tradingkey.logo
Search

Journey Medical Corp

DERM
Add to Watchlist
6.250USD
-0.080-1.26%
Close 05/18, 16:00ETQuotes delayed by 15 min
134.59MMarket Cap
LossP/E TTM

Journey Medical Corp

6.250
-0.080-1.26%

More Details of Journey Medical Corp Company

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Journey Medical Corp Info

Ticker SymbolDERM
Company nameJourney Medical Corp
IPO dateNov 12, 2021
CEOMaraoui (Claude)
Number of employees41
Security typeOrdinary Share
Fiscal year-endNov 12
Address9237 E Via De Ventura Blvd., Suite 105
CitySCOTTSDALE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code85258
Phone14804346670
Websitehttps://journeymedicalcorp.com/
Ticker SymbolDERM
IPO dateNov 12, 2021
CEOMaraoui (Claude)

Company Executives of Journey Medical Corp

Name
Name/Position
Position
Shareholding
Change
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.29M
+10.02%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
470.73K
+32.73%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
330.44K
-14.36%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
187.57K
+46.27%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
81.44K
-21.42%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
81.44K
-21.42%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
10.00K
-471.73%
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.29M
+10.02%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
470.73K
+32.73%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
330.44K
-14.36%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
187.57K
+46.27%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
81.44K
-21.42%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
81.44K
-21.42%

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
By BusinessUSD
Name
Revenue
Proportion
Qbrexa
25.01M
40.85%
Emrosi
14.74M
24.08%
Accutane
12.88M
21.04%
Amzeeq
5.86M
9.57%
Other branded revenue
2.74M
4.47%
By RegionUSD
Name
Revenue
Proportion
United States
61.86M
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Qbrexa
25.01M
40.85%
Emrosi
14.74M
24.08%
Accutane
12.88M
21.04%
Amzeeq
5.86M
9.57%
Other branded revenue
2.74M
4.47%

Shareholding Stats

Updated: Wed, May 13
Updated: Wed, May 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fortress Biotech Inc
15.74%
Maraoui (Claude)
10.73%
Wasatch Global Investors Inc
9.99%
Tang Capital Management, LLC
8.69%
Vanguard Capital Management, LLC
5.07%
Other
49.78%
Shareholders
Shareholders
Proportion
Fortress Biotech Inc
15.74%
Maraoui (Claude)
10.73%
Wasatch Global Investors Inc
9.99%
Tang Capital Management, LLC
8.69%
Vanguard Capital Management, LLC
5.07%
Other
49.78%
Shareholder Types
Shareholders
Proportion
Hedge Fund
21.80%
Investment Advisor/Hedge Fund
17.26%
Individual Investor
16.85%
Investment Advisor
16.39%
Corporation
15.74%
Private Equity
2.08%
Insurance Company
0.88%
Research Firm
0.44%
Pension Fund
0.24%
Other
8.31%

Institutional Shareholding

Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
137
12.08M
56.62%
+2.74M
2025Q4
111
6.92M
29.29%
--
2025Q3
113
6.92M
33.12%
+300.88K
2025Q2
111
6.62M
36.44%
+1.49M
2025Q1
80
5.12M
29.92%
+3.29K
2024Q4
74
3.80M
30.46%
+100.75K
2024Q3
75
2.18M
26.36%
-187.63K
2024Q2
70
2.37M
22.85%
+547.02K
2024Q1
61
1.83M
18.72%
-778.53K
2023Q4
59
1.36M
20.20%
-795.63K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Fortress Biotech Inc
3.36M
15.75%
--
--
Apr 14, 2025
Maraoui (Claude)
2.06M
9.66%
+1.24M
+150.79%
Aug 25, 2025
Wasatch Global Investors Inc
1.32M
6.17%
+10.00K
+0.77%
Dec 31, 2025
Tang Capital Management, LLC
1.85M
8.69%
--
--
Dec 31, 2025
Opaleye Management Inc.
975.00K
4.57%
+3.94K
+0.41%
Dec 31, 2025
J. Goldman & Co., L.P.
798.37K
3.74%
+798.37K
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
655.76K
3.07%
+83.84K
+14.66%
Dec 31, 2025
Alloush (Ramsey)
316.68K
1.48%
+46.86K
+17.37%
Jun 17, 2025
Millennium Management LLC
457.81K
2.15%
+457.81K
--
Dec 31, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
Royce Quant Small-Cap Quality Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Royce Quant Small-Cap Quality Value ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI